Pakes G E
Medical Publications Residency, GlaxoSmithKline, Research Triangle Park, NC, USA.
Ann Pharmacother. 2001 Jun;35(6):770-9. doi: 10.1345/aph.10252.
Once researchers have completed a clinical trial and analyzed the data, they have a duty to make the results known to their peers by writing a manuscript suitable for publication in a biomedical journal. Before beginning any writing, those involved in the clinical drug trial first need to decide among themselves who is to be the first author and secondary authors, the readership they want to influence, and the most appropriate target journal to reach this readership. For content and formatting of the manuscript, writers need to carefully follow the instructions for authors as stipulated by the target journal. In general, a manuscript based on a clinical trial is presented sequentially in four sections: Introduction, Methods, Results, and Discussion (IMRAD). The introduction concisely presents background information about the topic that was researched in the clinical trial, provides the study hypothesis, and describes the study rationale, purpose, and objectives. The Methods section delineates the study design, subject/patient selection process, procedures, end points, and types of analysis conducted in the clinical trial to investigate the study hypothesis. The Results section presents the findings of the clinical trial, and the Discussion section interprets the meaning of these findings, assesses how the findings answer the study hypothesis, and compares the study data with findings reported in earlier studies. Writers should select a title for the clinical trial manuscript that is fewer than 10 words and which embodies the essence of the study findings clearly and specifically without being sensationalistic. Writers should create the abstract last; the abstract should provide an overview of the manuscript and stimulate readers' interest. Overall, following the above principles in writing a manuscript based on a clinical drug trial will make the actual writing easier and more enjoyable, as well as increase the possibility of the manuscript being accepted for publication.
一旦研究人员完成了一项临床试验并分析了数据,他们就有责任通过撰写一篇适合在生物医学期刊上发表的稿件,将结果告知同行。在开始任何写作之前,参与临床药物试验的人员首先需要自行决定谁将担任第一作者和第二作者,他们想要影响的读者群体,以及针对该读者群体最合适的目标期刊。对于稿件的内容和格式,作者需要仔细遵循目标期刊规定的作者指南。一般来说,基于临床试验的稿件按顺序分为四个部分呈现:引言、方法、结果和讨论(IMRAD)。引言简要介绍临床试验中所研究主题的背景信息,提供研究假设,并描述研究原理、目的和目标。方法部分阐述研究设计、受试者/患者选择过程、程序、终点以及在临床试验中为调查研究假设而进行的分析类型。结果部分呈现临床试验的发现,讨论部分解释这些发现的意义,评估这些发现如何回答研究假设,并将研究数据与早期研究报告的发现进行比较。作者应为临床试验稿件选择一个少于10个单词的标题,该标题应清晰、具体地体现研究发现的本质,而不哗众取宠。作者应最后撰写摘要;摘要应提供稿件的概述并激发读者的兴趣。总体而言,在撰写基于临床药物试验的稿件时遵循上述原则,将使实际写作更加轻松愉快,同时增加稿件被接受发表的可能性。